- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
Patent holdings for IPC class A61K 31/4174
Total number of patents in this class: 959
10-year publication summary
|
81
|
77
|
72
|
90
|
94
|
88
|
76
|
76
|
65
|
42
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bioxcel Therapeutics, Inc. | 80 |
50 |
| Allergan, Inc. | 2159 |
48 |
| Allergan Holdings Unlimited Company | 37 |
10 |
| The Rockefeller University | 583 |
10 |
| Teikoku Pharma USA, Inc. | 86 |
10 |
| Clexio Biosciences Ltd. | 100 |
10 |
| Bristol-myers Squibb Company | 4748 |
9 |
| The Regents of the University of California | 20802 |
9 |
| Hisamitsu Pharmaceutical Co., Inc. | 775 |
9 |
| Case Western Reserve University | 1898 |
7 |
| Galderma Research & Development | 351 |
7 |
| Mayne Pharma LLC | 57 |
7 |
| Orion Corporation | 775 |
7 |
| EPI Health, LLC | 10 |
7 |
| ARx, LLC | 24 |
6 |
| Cmpd Licensing, LLC | 83 |
6 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3333 |
6 |
| Mitobridge, Inc. | 31 |
6 |
| Nicox Ophthalmics, Inc. | 21 |
6 |
| Sol-gel Technologies Ltd. | 117 |
6 |
| Other owners | 723 |